Printer Friendly

VILLAFANA ANNOUNCES ATS MEDICAL, INC. SECOND QUARTER RESULTS

 MINNEAPOLIS, July 26 /PRNewswire/ -- ATS Medical, Inc. (NASDAQ-NMS: ATSI) reported net sales of $1,433,560 for the second quarter ended June 30, 1993, representing sales of the ATS Open Pivot Bileaflet(TM) valve for human implant in international markets. The company reported $1,000,900 in sales for the first quarter of 1993 and reported $82,380 in sales for the corresponding second quarter of 1992, when the valve was first sold.
 Manny Villafana, chairman and chief executive officer, expressed satisfaction with the increase in sales as well as the company's ability to manufacture a sufficient number of valves to satisfy its back orders. "By the end of the second quarter, we reached the production level that we had hoped we would reach by the end of the year," commented Villafana.
 Villafana added, "As we look into the third quarter, we have to recognize that sales will be hampered by the fact that during the summer months there are virtually no implants in Europe. We will try our best to strengthen the third quarter by conducting our First International Symposium in Spain, where many of the physicians studying the valve will review the initial clinical results."
 ATS Medical, Inc. currently has over 40 physicians throughout Europe and Argentina studying the valve. Villafana noted that the company has not received any reports of any valve-related complications. "This is becoming significant, as we now have valves implanted in excess of one year," stated Villafana.
 ATS Medical, Inc. manufactures and markets a new pyrolytic carbon bileaflet mechanical heart valve. The company's common stock is traded on the NASDAQ - National Market System under the symbol "ATSI."
 ATS MEDICAL, INC.
 CONSOLIDATED CONDENSED STATEMENT OF OPERATIONS
 (Unaudited)
 Three months ended Six months ended
 6/30/93 6/30/92 6/30/93 6/30/92
 Net sales $1,433,560 $82,380 $2,434,460 $82,380
 Cost of goods sold $837,202 $54,891 $1,487,099 $54,891
 Gross profit $596,358 $27,489 $947,361 $27,489
 Research, develop-
 ment and engineering
 expenses $142,947 $448,590 $215,123 $952,840
 Selling, general and
 administrative ex-
 penses $608,871 $601,940 $1,318,521 $1,128,155
 Net loss $(108,424) $(981,689) $(472,442)$(1,959,296)
 Net loss per share $(0.01) $(0.11) $(0.04) $(0.21)
 Weighted average
 number of shares
 outstanding 10,846,214 9,205,414 10,843,036 9,205,372
 -0- 7/26/93
 /CONTACT: Manny Villafana, chairman/CEO; Richard Kramp, president/COO; Jack Jungbauer, treasurer/CFO; all of ATS Medical, 612-553-7736/
 (ATSI)


CO: ATS Medical, Inc. ST: Minnesota IN: MTC SU: ERN

DB -- MN023 -- 5913 07/26/93 17:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 26, 1993
Words:448
Previous Article:ELTRAX REPORTS FIRST QUARTER RESULTS
Next Article:CRAY RESEARCH REPORTS SECOND QUARTER RESULTS; MAINTAINS EXPECTATIONS FOR A SIGNIFICANTLY IMPROVED YEAR
Topics:


Related Articles
ATS MEDICAL ANNOUNCES SECOND QUARTER RESULTS
ATS MEDICAL, INC. ANNOUNCES SUCCESSFUL FINANCING AND THIRD QUARTER RESULTS
VILLAFANA ANNOUNCES ATS MEDICAL, INC. YEAR END RESULTS
VILLAFANA ANNOUNCES ATS MEDICAL, INC. FIRST QUARTER RESULTS
ATS MEDICAL, INC. ANNOUNCES RECORD FOURTH QUARTER RESULTS AND CONTINUED CLINICAL SUCCESS WITH ITS HEART VALVE
MANNY VILLAFANA ANNOUNCES ATS MEDICAL, INC. AUDITED YEAR END RESULTS
MANNY VILLAFANA ANNOUNCES ATS MEDICAL, INC. FIRST QUARTER RESULTS
MANNY VILLAFANA OF ATS MEDICAL ANNOUNCES PROFITABILITY AND ALLOWANCE OF PATENT
MANNY VILLAFANA ANNOUNCES 30% INCREASE IN SALES AND SUBMISSION OF IDE TO U.S. FDA
MANNY VILLAFANA ANNOUNCES ATS MEDICAL, INC. RECORD FOURTH QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters